Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?

Core Viewpoint - Pfizer's recent earnings report shows a mixed performance, with adjusted earnings per share beating estimates but revenues declining, particularly from COVID-19 products, raising questions about future growth potential [2][3][18]. Financial Performance - Q4 2025 adjusted earnings per share were 66 cents, exceeding the Zacks Consensus Estimate of 57 cents, marking a 5% year-over-year increase due to cost savings and gross margin expansion [2]. - Total revenues for Q4 2025 were $17.6 billion, down 1% year-over-year on a reported basis and 3% operationally, primarily due to a 40% decline in revenues from COVID-19 products [3]. - Non-COVID product sales rose 9% operationally in Q4, driven by products like Eliquis and the Prevnar family, while full-year 2025 sales declined 2% to $62.6 billion but still beat estimates [4][18]. Segment Performance - Primary Care segment revenues fell 13% operationally to $7.94 billion, while Specialty Care grew 6% to $4.77 billion, and Oncology sales rose 8% to $4.44 billion [6]. - Eliquis sales increased 8% to $2.02 billion, but alliance revenues missed estimates [7]. Prevnar family revenues rose 8% to $1.71 billion, exceeding estimates [8]. - Comirnaty sales were $2.27 billion, down 35% year-over-year, while Paxlovid revenues dropped 70% to $218 million, both missing estimates [9][10]. Cost Management - Adjusted selling, informational, and administrative expenses decreased 5% to $4.08 billion due to productivity improvements, while adjusted R&D expenses rose 4% to $3.12 billion [5]. Future Guidance - For 2026, Pfizer expects total revenues between $59.5 billion and $62.5 billion, reflecting a decline from 2025 due to lower COVID product revenues and a projected $1.5 billion impact from patent expirations [19][20]. - Adjusted earnings per share for 2026 are forecasted to be between $2.80 and $3.00, down from $3.22 in 2025 [21]. Pipeline and Strategic Initiatives - Pfizer plans to initiate 20 pivotal studies in 2026, focusing on obesity and oncology programs, indicating a catalyst-rich year ahead [24].